Study Comparing the Use of Remifentanil Versus Propofol for Performing Bronchial Fibroscopy

• Status: Completed
• Trial end date: 2017-04-03
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the use of Target-Controlled Infusion (TCI) of Remifentanil can deliver better conditions for performing bronchial fibroscopy with spontaneous ventilation (decrease the duration of cough) compared to the use of TCI of Propofol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Treatments: Propofol; Remifentanil

Criteria

Inclusion Criteria:

• Patient major with consent

• Patient with an indication of bronchoscopy under intravenous sedation:

• Cough making endoscopy impossible despite local anesthesia

• Refusal of the patient to undergo the action without sedation

• There is no limitation related to the type of pathology: it is patient "all comers"

Exclusion Criteria:

• Patients with a known allergy to Remifentanil

• Patients with a known allergy to Propofol, soy, peanuts

• Pregnant women or nursing

• Neurological pathology causing intracranial hypertension

• Patients with a Body Mass Index greater than 30

• Indications of orotracheal intubation :

• Protection of the upper airways: patient considered "full stomach": Diabetes with autonomic dysfunction, severe gastroesophageal reflux, severe obesity and morbid hiatal hernia and any other situation governed by the anesthesiologist as a situation of full stomach

• The need for mechanical ventilation severe hypoxemia

• Cirrhosis child B and C

• Intermittent or severe uncontrolled asthma